Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)
Develop advanced technology to improve early detection of aggressive cancer and identify precancerous lesions associated with lethal outcomes using integrated imaging, biomarkers, and digital pathology.
Browse similar grants
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision)
Funding Amounts: No budget limit; budgets must reflect actual project needs. Maximum project period: 5 years.
Summary: Supports research integrating imaging, biomarkers, and digital pathomics to improve early detection of aggressive cancer and identification of precancerous lesions with lethal potential.
Key Information: Clinical trial proposals are optional; all funded projects will participate in the Consortium for Imaging and Biomarkers (CIB) program.
Description
This NIH funding opportunity supports the development of advanced, multidisciplinary research projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, and other omics data to improve the early detection of aggressive, organ-confined premetastatic cancers and to identify precancerous lesions associated with subsequent lethal phenotypes. The initiative aims to address diagnostic uncertainty in clinical decision-making by enhancing the sensitivity and specificity of integrated, multiparametric platforms.
Projects may leverage a range of analytic strategies, including artificial intelligence and virtual reality visualization, to co-register and cross-correlate imaging and biomarker data. All funded projects will participate in the Consortium for Imaging and Biomarkers (CIB) Research Program, fostering collaboration and resource sharing among awardees.
